ArticleFrontiers in pharmacology2026
Preliminary exploration of acute limit toxicity testing for nicotinamide mononucleotide in the neonatal population.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study investigated the potential toxicity of nicotinamide mononucleotide (NMN) during the neonatal period, a critical and vulnerable developmental window. While NMN, a precursor of NAD Methods: We conducted an acute limit toxicity test to evaluate the impact of NMN on vital organs (liver, kidney, and central nervous system) in neonatal mice. Results: Under these experimental conditions, no significant acute toxicity was observed, with no histopathological damage or serum biochemical abnormalities detected in the major organs. However, high-throughput transcriptome sequencing revealed subtle yet specific gene expression perturbations, involving liver proliferation signal regulation, kidney adaptation to excretory load, and brain suppression of neuroinflammation alongside coordinated growth and metabolism. Discussion: Despite the absence of overt histopathological or clinical toxicity, transcriptomic analysis revealed that a single high-dose NMN exposure may induce early molecular-level stress and compensatory adjustments in neonates. These findings provide crucial preliminary experimental evidence and transcriptomic insights for assessing NMN safety in early life, highlighting the need for future studies on long-term, subchronic, and chronic effects, while noting that the results cannot be directly extrapolated to human infants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.